Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120525 | 1.00 | GPR119 (0.67) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL10106428 | 1.00 | GPR119 (0.67) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL10106437 | 1.00 | GPR119 (0.67) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL10106381 | 0.96 | GPR119 (0.62) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12236503 | 0.93 | GPR119 (0.76) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12275991 | 0.87 | GPR119 (0.53) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12276652 | 0.87 | GPR119 (0.53) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12320310 | 0.87 | GPR119 (0.58) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12276897 | 0.87 | GPR119 (0.58) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL12236482 | 0.86 | GPR119 (0.67) | GPR119CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907095-B2 | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 | MERCK SHARP & DOHME CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885CHRM2 2244/4885CHRM1 2211/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | GPR119 1/4885CHRM2 1266/4885CHRM1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.